Long-term efforts by Avecho Biotechnology (ASX: AVE) to further the clinical and commercial potential of its TPM (tocopheryl phosphate mixture) enhanced products gained traction during the three months to end June.
The US Patent and Trade Marks Office has allowed Avecho Biotechnology (ASX: AVE) a new patent application directed to an optimised manufacturing process for its drug delivery system tocopheryl phosphate mixture (TPM).
Avecho Biotechnology (ASX: AVE) has signed an agreement with Arthur Group LLC for the licensing and development of a series of leading cancer drugs using tocopherol phosphate mixture (or TPM) to replace conventional adverse solvents or surfactants.
Melbourne-based Avecho Biotechnology (ASX: AVE) is seeking to raise $11 million to fund a pivotal clinical trial evaluating the use of its cannabinoid (CBD) soft-gel capsule to treat insomnia.